Sionna therapeutics reports fourth quarter and full year 2024 financial results

Phase 1 mad dosing completed for sion-451 and final mad cohort of sion-719 planned; interim data in healthy volunteers show potential to provide clinically meaningful benefit to cf patients. topline data anticipated in first half of 2025
SION Ratings Summary
SION Quant Ranking